北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会的法律意见书 嘉源(2025)-04-952 北京市嘉源律师事务所(以下简称"本所")接受深圳惠泰医疗器械股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《深 圳惠泰医疗器械股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第四次临时股东会(以下简称"本次股东会")进行见 证,并依法出具本法律意见书。 北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会的法律意见书 西城区复兴门内大街158 号远洋大厦 4 楼 中国 · 北京 T CUMERS Pr YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳惠泰医疗器械股份有限公司 一、本 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-062 深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 25 日 （二） 股东会召开的地点：上海市徐汇区田林路 487 号宝石园 20 栋宝石大厦 22 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 275 | | --- | --- | | 普通股股东人数 | 275 | | 2、出席会议的股东所持有的表决权数量 | 79,112,943 | | 普通股股东所持有表决权数量 | 79,112,943 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 62.4022 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 62.4022 | ...

Core Insights - The report recommends focusing on the CXO sector within the pharmaceutical and biotechnology industry, highlighting its global competitiveness and long-term growth potential [6][4] - The investment strategy maintains an "outperform" rating for the sector, with a specific portfolio of recommended stocks for December 2025 [2][6] Industry Overview - The pharmaceutical manufacturing industry saw a cumulative revenue of 199.55 billion yuan from January to October 2025, reflecting a year-on-year decline of 2.9%, while total profits decreased by 3.5% to 26.98 billion yuan [10][9] - The retail sales of Western and Chinese medicines reached 595.5 billion yuan, with a modest growth of 1.5% year-on-year [10][9] Investment Strategy - The recommended investment portfolio for December 2025 includes notable A-shares such as Mindray Medical (迈瑞医疗), WuXi AppTec (药明康德), and Aier Eye Hospital (爱尔眼科), among others [6][7] - The report emphasizes the importance of monitoring the clinical progress and data readouts of innovative drugs in overseas markets, as these factors can enhance the commercial viability of domestic products [6] Market Performance - The pharmaceutical sector experienced a decline of 3.62% in November 2025, underperforming the CSI 300 index by 1.16% [11] - The medical services sub-sector faced the most significant drop, with a decrease of 7.77%, while the pharmaceutical commercial sector saw a slight increase of 1.27% [17][11] Valuation Insights - The overall valuation of the pharmaceutical sector is relatively high, with a current PE (TTM) of 37.71, placing it at the 79.87 percentile of its historical range over the past five years [19][20] - The premium rates of the pharmaceutical sector compared to the CSI 300 and the entire A-share market remain at historical averages [19][20] Recent Developments - In November 2025, eight innovative drugs or biosimilars were approved for market entry, including products from Pfizer and domestic companies, indicating a robust pipeline for new therapies [25][26] - The report tracks the NDA and IND applications for innovative drugs, highlighting ongoing research and development activities within the industry [27][28]

展望2026年，AI算力、自主可控有望进入景气兑现期，将为科创板基本面提供一定支撑，在政策支 持"硬科技"导向明确的背景下，科创板有望在AI浪潮下持续受益。 截至14点39分，A股三大指数全线上涨，上证指数涨0.51%，深证成指涨0.79%，创业板指涨0.70%。科 创50ETF（588000）上涨0.85%，冲击日线4连阳，今日最新报价1.422元，盘中成交额达26.25亿元，换 手率3.49%。成分股方面涨跌互现，天岳先进领涨6.62%，恒玄科技上涨6.28%，中芯国际上涨2.74%， 澜起科技上涨0.64%，海光信息上涨0.22%；华海清科领跌2.26%，拓荆科技下跌2.25%，百利天恒下跌 2.19%，惠泰医疗下跌2.03%，金山办公下跌0.36%。 资金流入方面，科创50ETF近10个交易日内，有6个交易日获资金净流入，合计净流入10.15亿元，日均 净流入达1.02亿元。 （文章来源：每日经济新闻） ...

Group 1 - On December 24, 13 companies announced progress related to stock repurchase plans, including one company disclosing a new repurchase plan, one company obtaining shareholder approval for a repurchase plan, one company revealing implementation progress, and ten companies completing their repurchase plans [1] - The company Weimaisi announced the highest repurchase plan amount, proposing to repurchase up to 100 million yuan [1] - The company Fanwei Network had the highest repurchase amount approved by shareholders, proposing to repurchase up to 158 million yuan [1] Group 2 - The company Dong'a Ejiao reported the highest repurchase amount in progress, having repurchased 19.9976 million yuan [1] - Among the companies that have completed repurchases, seven companies reported amounts exceeding 10 million yuan, with Baiwei Storage, Zhongyan Chemical, and Maiwei Biological-U having the highest completed repurchase amounts of 150 million yuan, 67.0411 million yuan, and 49.9945 million yuan respectively [1] - As of December 24, a total of 1,992 repurchase plans have been implemented this year, involving 1,434 companies, with 389 companies completing repurchases exceeding 100 million yuan [1] - The companies Midea Group, Kweichow Moutai, and Muyuan Foods reported the highest completed repurchase amounts of 10.035 billion yuan, 6 billion yuan, and 3 billion yuan respectively [1]

沪深300今日主力资金净流出76.96亿元，创业板净流出89.34亿元，科创板净流出15.25亿元。 | | 各板块最近五个交易日主力资金净流入数据(亿元) | | | | --- | --- | --- | --- | | 日期 | 沪深300 | 创业板 | 科创板 | | 2025-12-23 | -76.96 | -89. 34 | -15. 25 | | 2025-12-22 | 28. 91 | 20. 31 | -12. 07 | | 2025-12-19 | 9.88 | -38. 81 | 9.25 | | 2025-12-18 | -152. 56 | -101. 40 | -7.88 | | 2025-12-17 | 51. 45 | 40. 67 | -15. 20 | | | | 尾盘资金净流入数据(亿元) | | | 2025-12-23 | -14.66 | -19. 42 | -3.50 | | 2025-12-22 | 1. 21 | -2. 24 | 2. 46 | | 2025-12-19 | -3. 61 | -7.53 | 2. 93 | | 2025-12-18 | ...

12月23日，A股市场整体涨跌互现。 沪深300今日主力资金净流出76.96亿元，创业板净流出89.34亿元，科创板净流出15.25亿 元。 | | 各板块最近五个交易日主力资金净流入数据(亿元) | | | | --- | --- | --- | --- | | 日期 | 沪深300 | 创业板 | 科创板 | | 2025-12-23 | -76.96 | -89. 34 | -15. 25 | | 2025-12-22 | 28. 91 | 20. 31 | -12. 07 | | 2025-12-19 | 9.88 | -38. 81 | 9.25 | | 2025-12-18 | -152.56 | -101.40 | -7.88 | | 2025-12-17 | 51. 45 | 40. 67 | -15. 20 | | | | 尾盘资金净流入数据(亿元) | | | 2025-12-23 | -14.66 | -19.42 | -3. 50 | | 2025-12-22 | 1. 21 | -2.24 | 2. 46 | | 2025-12-19 | -3. 61 | -7.53 | 2.93 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The report highlights the increasing support from policies aimed at enhancing service consumption, particularly in the healthcare sector, indicating potential investment opportunities in medical services [2][11] - The "reward economy" is emerging as a new consumption model, where consumers are more willing to spend on non-essential goods and services, especially in healthcare, after meeting basic needs [13][14] - The medical services market in China is projected to reach approximately 8.74 trillion yuan by 2025, with a year-on-year growth rate exceeding 10% [15] Summary by Sections Market Performance - The overall A-share market declined by 0.07%, with the pharmaceutical and biotechnology sector down by 0.14%, underperforming the broader market [23] - Within the sector, chemical pharmaceuticals fell by 1.74%, while medical services and medical devices saw increases of 0.55% and 1.16%, respectively [23] Policy Support - Recent policies have focused on boosting service consumption, with a clear goal of enhancing service quality and expanding supply in key areas such as healthcare [11][12] - The government aims to stimulate demand through financial tools and support for service industries, which is expected to benefit the healthcare sector significantly [11] Investment Opportunities - Companies such as Aier Eye Hospital and Guosheng Tang are highlighted as leading firms in the medical services sector, benefiting from their innovative capabilities and market positioning [16][19] - The report suggests focusing on companies with strong optionality and innovative business models in the medical services space [16] Company Forecasts and Ratings - Major companies in the sector, including Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with positive profit forecasts for the coming years [4][32] - For instance, Aier Eye Hospital is expected to see significant growth driven by new refractive surgery techniques [19] Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is reported at 37.07x, compared to the overall A-share market at 20.54x [28]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][5] Core Insights - The medical consumables sector saw a weekly increase of 2.29%, outperforming the CSI 300 index by 0.14 percentage points [2][4] - The current PE (ttm) for the medical consumables sector is 35.38X, with a PB (lf) of 2.54X, indicating a slight increase in valuation metrics compared to the previous week [3][16] - Recent policy changes from the National Health Commission aim to enhance the capabilities of grassroots medical institutions, which is expected to drive demand for specialized medical equipment and consumables [4][19] - The initiation of centralized procurement for high-frequency electric knives across 29 provinces presents opportunities for domestic brands to gain market share [4][20][22] Summary by Sections Industry Performance - The medical consumables sector reported a weekly increase of 2.29%, with a current index value of 5840.56 points [2][8] - The sector's performance over the past 12 months shows a relative decline of 9% compared to the CSI 300 index [2] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 35.38X, with a year-to-date maximum of 40.1X and a minimum of 28.88X [3][16] - The PB ratio stands at 2.54X, with a maximum of 2.92X and a minimum of 2.13X over the past year [3][18] Industry Dynamics and Announcements - The National Health Commission's new guidelines encourage grassroots medical institutions to upgrade from general to specialized departments, increasing the demand for specific medical consumables [4][19] - The centralized procurement initiative for high-frequency electric knives is expected to facilitate domestic brands' entry into mainstream hospitals, with a pricing mechanism that rewards product differentiation [4][20][22] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly those benefiting from domestic substitution and policy guidance in the rehabilitation and chronic disease management sectors [5][24] - Specific companies to watch include those with diverse product lines and high innovation in high-value consumables, such as electrophysiology and interventional products [5][24]

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]